Introduction

The Department of Oncology stands as a cornerstone clinical discipline at Shanghai Sixth People's Hospital. Established in 2002, it has transformed from a singular chemotherapy treatment center to a comprehensive department integrating medicine, teaching, research, and prevention. Continuously advancing, it exemplifies the hospital's dedication to spiritual and civilizational excellence. With a tumor research facility and a bone and soft tissue tumor specimen bank, the department encompasses two wards at Xuhui Campus, offering 43 licensed beds and 19 day beds. Staffed by 14 proficient doctors, all holding PhD or master's degrees, with 80% being PhDs, alongside 2 chief physicians, 8 deputy chief physicians, 2 doctoral supervisors, and 3 master's degree supervisors, the department is committed to excellence. Additionally, the Lingang campus features 41 licensed beds, 9 clinicians, 1 chief physician, and 1 doctoral supervisor, all with doctorate or master's degrees. Specializing in solid tumor diagnosis and comprehensive internal medicine treatment, the department collaborates with sister departments to establish a comprehensive tumor treatment system. Recognized as doctoral and master's degree awarding sites in oncology at Shanghai Jiao Tong University School of Medicine and Soochow University School of Medicine, and postdoctoral stations, the department has led numerous national research endeavors and earned accolades, including the second prize of National Science and Technology Progress Award (as the second completing unit). Furthermore, it conducts multiple national-level continuing education projects annually.

Specialties

1. The department conducts comprehensive medical treatment and regular follow-ups for various solid tumors. With extensive clinical expertise spanning systemic tumor chemotherapy, intracavitary chemotherapy, immunotherapy, cell therapy, endocrine therapy, molecular targeted therapy, tumor hyperthermia, treatment of tumor complications, and oncology emergencies.
2. Distinguished for its expertise in bone and soft tissue sarcoma diagnosis and treatment, the department has conducted fundamental and clinical research for over a decade. Leading the nation in comprehensive treatment, it serves the largest number of patients in East China and ranks among the top three nationwide. Collaborating with the Department of Bone Oncology, Pathology, Imaging, Thoracic Surgery, it established the Comprehensive Diagnosis and Treatment Center for Bone and Soft Tissue Tumors. Pioneering a multidisciplinary diagnosis and treatment model, it maximizes limb function preservation, minimizes recurrence and metastasis, enhances cure rates, and prolongs survival. Additionally, the department is at the forefront of developing first-in-class drug candidates for sarcoma, revolutionizing diagnosis and treatment strategies.
3. The department specializes in local tumor diagnosis and treatment, annually performing over 3,000 surgical operations including trans-arterial interventional tumor embolization, puncture biopsy, local ablation, and infusion port implantation. Particularly adept in challenging and complex tumor biopsy, relapse, and refractory treatment, it continues to innovate transformative tumor treatments, advancing the clinical significance of local treatment in the sarcoma field.
4. Representing the latest diagnostic and treatment concept in bone metastasis cancer, the department's individualized comprehensive diagnosis and treatment process demonstrates high clinical operability. Its surgical treatment, bone cement treatment, and external radiation therapy technology for bone metastasis cancer are nationally leading.